Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting
PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting 86% of patients evaluated achieved at least 50% nodule volume reduction at six months after a single nonthermal nsPFA treatm
How this was made
The 30-second read
Why it matters
The data suggest the device is effective and safe, which could accelerate commercialization and attract partnership interest.
Market read
First disclosure of meaningful clinical data for a small‑cap med‑tech firm, likely to move the stock.
What to watch
Potential regulatory hurdles and reimbursement uncertainty could temper upside.
Background
Pulse Biosciences filed an 8‑K announcing interim results from its multicenter study of the nPulse Vybrance system for benign thyroid nodules.
Ticker impact
Interim six‑month data from the PRECISE‑BTN study showed 86% of patients achieved ≥50% nodule reduction, indicating strong efficacy and safety.
upward pressure as the market prices in the strong efficacy and safety data
The data represent a material clinical milestone for a small‑cap med‑tech firm, often translating into near‑term price appreciation.
Market effects
May validate nanosecond pulsed field ablation technology, benefiting peer med‑tech devices.
U.S. biotech sector could see modest uplift.
Limited to niche med‑tech investors.
Counterpoint
Skeptics may argue interim data are insufficient without 12‑month outcomes.
Key entities
- companyPulse Biosciences, Inc.
Nanosecond pulsed field ablation device maker.
- personRalph Tufano, MD
Principal investigator presenting the study.
